| 1 |
Abeta (1-42) increases dopamine release in the prefrontal cortex |
| 2 |
Abeta antagonizes alpha7 nAChR receptors; opposed by nicotine. |
| 3 |
Abeta blocks voltage-gated Na+ channels in GABA neurons causing abberant excitation |
| 4 |
Abeta causes selective neuronal mortality. This requires cell membrane binding. |
| 5 |
Abeta decreases apical dendrite arborizations in cortical pyramidal cells in transgenic mice |
| 6 |
Abeta decreases dedritic spine number and alters dendritic spine morpholology |
| 7 |
Abeta decreases dendritic spine density and motility, increases spine legth. Rolipram blocks these e |
| 8 |
Abeta decreases dendritic spine number, causes dysmorphic spine shapes |
| 9 |
Abeta decreases p-21 activated kinase and causes cofilin pathology |
| 10 |
Abeta increase in A-type K+ current is caused by modulation of Kv4 subunit expression |
| 11 |
Abeta inhibits late LTP in animal models of Alzheimers |
| 12 |
Abeta inhibits LTP both in soluble and fibrillar conformational states |
| 13 |
Abeta inhibits LTP through TNFalpha |
| 14 |
Abeta inhibits nicotinic ACh receptors at pre-synaptic glutamatergic terminals |
| 15 |
Abeta inhibits PAK, stimulates ROCK and impairs synapses by TLR signaling |
| 16 |
Abeta modulates A current (HEK293 cells) |
| 17 |
Abeta oligomer causes aberrant activity of p-21 activated kinase |
| 18 |
Abeta oligomer inhibits p-21 activated kinase and stimulates ROCK signalling |
| 19 |
Abeta peptides block LTP in rat CA1 in vivo |
| 20 |
Abeta-derived diffusible ligands (ADDLs) attack synapses at or near NMDA receptors |
| 21 |
Abeta42/Abeta40 ratio correlates with impaired LTP in a mouse model of Alzheimers |
| 22 |
ACh Esterase inhibitors decrease Abeta production by influencing APP processing |
| 23 |
AD combined treatment with cholinesterase inhibitor and alpha-adrenergic agonist. |
| 24 |
Aging causes reduction in dendrite complexity, spine loss, decreased glutamate, increased GABA |
| 25 |
Aging decreases NMDA receptors and increases GABA A-receptor mediated inhibition |
| 26 |
Alpha4beta2 receptor blockade causes memory impairment |
| 27 |
Aluminum alters GABAA receptors |
| 28 |
AMPA receptor downscaling in AD |
| 29 |
Amyloid plaques increase elimination of dendritic spines |
| 30 |
Apolipoprotein E4 (Apo E4) levels are inversely correlated with dendritic spine density |
| 31 |
BACE1 required for LTP at mossy fiber-CA3 synapses |
| 32 |
beta Amyloid increases calcium currents |
| 33 |
beta Amyloid increases calcium currents (2) |
| 34 |
beta-Amyloid activates I_L by MAP Kinase |
| 35 |
Beta-amyloid blocks high frequency stimulation induced LTP but not nicotine enhanced LTP |
| 36 |
beta-Amyloid impairs LTP/LTD |
| 37 |
beta-Amyloid potentiates Ca influx through L-type Ca channels |
| 38 |
beta-amyloid reduces IA |
| 39 |
beta-Amyloid-induced depression of LTP attenuated by Verapamil |
| 40 |
Chronic nicotine decreases NGF and improves memory performance |
| 41 |
Co-localization of amyloid beta and tau in Alzheimer's disease synaptosomes. |
| 42 |
DHA increases dendritic spines and synapses; enhanced by uridine and choline |
| 43 |
Donepezil modulates potassium channels |
| 44 |
Drebrin decrease causes cognitive deficits but does not affest spatial memory |
| 45 |
Drebrin decrease in frontal cortex correlated with mild Alzheimer's disease |
| 46 |
Galantamine increases dopamine release in the hippocampus |
| 47 |
Ginkgolides protect against amyloid-beta1-42-mediated synapse damage in vitro. |
| 48 |
Glutamatergic synaptic depression by synthetic amyloid beta-peptide in the medial septum. |
| 49 |
Histidine associating compounds block Abeta Channel activity and cytotoxicity |
| 50 |
Inhibition of I_L impairs LTP in CA1 in vivo |
| 51 |
Large decrease in spines in plaque-free regions of dentate gyrus in APP/PS1 mice |
| 52 |
LTP requires BDNF and is associated with cytoskeleton-associated protein |
| 53 |
Memantine reduces APP, Galantamine and Nicotine increase synaptophysin |
| 54 |
Memory loss caused by beta-amyloid protein is rescued by a beta(3)-adrenoceptor agonist |
| 55 |
Model block of I_A |
| 56 |
Muscarinic receptor agonists and nicotine may prevent neurodegeneration in AD |
| 57 |
Neurocortical synapse density decrease correlates with cognitive decline much more strongly than pla |
| 58 |
Neurofibrillary tangles are correlated with spinophilin and with Alzheimer's cognitive decline |
| 59 |
NGF restores dendritic spine density in Layer V pyramidal neurons |
| 60 |
Nicotine decreases intracellular copper concentration; attenuates Abeta toxicity |
| 61 |
Nicotine decreases intracellular Cu+2 concentration. Abeta increases. |
| 62 |
Nicotine desensitize alpha7 nACh receptors and facilitates LTP |
| 63 |
Nicotine enhances depressive actions of Abeta on LTP in rat CA1 region in vivo |
| 64 |
Nicotine increases APP and APLP2 gene expression |
| 65 |
Okadaic acid mediates tau phosphorylation via L channel activation |
| 66 |
p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro |
| 67 |
Phosphatidyl serine (BC-PS) decreases dendritic spine loss |
| 68 |
Picomolar concentrations of abeta monomers disrupt LTP |
| 69 |
Post-synaptic Drebrin correlated with Alzheimer's cognitive decline |
| 70 |
Postsynaptic calcium concentration in aging neurons is closely associated with altered plasticity. |
| 71 |
Presenilin-1 deficient neurons have increased activity of L channels |
| 72 |
Protective effect of donepezil against beta amyloid neurotoxicity |
| 73 |
Protofibrillar intermediates of ABeta change firing pattern of neurons. |
| 74 |
Regulation of back-propagating action potentials in hippocampal neurons. |
| 75 |
Serum magnesium level correlates with clinical deterioration in Alzheimer's |
| 76 |
Sub-nanomolar concentrations of oligomeric beta amyloid inhibits late LTP in rats and mice |
| 77 |
Synapse Loss correlated with cognitive loss in mild Alzheimer's Disease |
| 78 |
Synaptic integration is disrupted in an AD mouse model |
| 79 |
The channel hypothesis of Alzheimers disease |